Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now
Yahoo FinanceApr 2 07:00 ET
Dermata to Present at the Emerging Growth Conference on April 3, 2024
- Dermata to provide a corporate update followed by a live question and answer session -SAN DIEGO, CA / ACCESSWIRE / March 27, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) ("Dermata" or the
AccesswireMar 27 16:05 ET
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results
AccesswireMar 21 16:05 ET
Dermata to Present at the Emerging Growth Conference on February 7, 2024
- Company to provide a corporate overview followed by a live question and answer session -SAN DIEGO, CA / ACCESSWIRE / February 1, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Derma
AccesswireFeb 1 09:00 ET
Why Dermata Therapeutics Stock Took Off After-Hours
Dermata Therapeutics, Inc. (NASDAQ:DRMAW) shares are trading higher in Thursday's after-hours session after the company announced the issuance of a new patent in Japan for its DMT410 program for the
BenzingaJan 4 17:31 ET
Dermata Expands Global Intellectual Patent Portfolio With Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis
AccesswireJan 4 16:06 ET
Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
SAN DIEGO, CA / ACCESSWIRE / November 16, 2023 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment o
AccesswireNov 16, 2023 13:30 ET
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
- Raised an aggregate of $6.8 million in gross proceeds from two financings completed in 1H 2023 -- Received positive feedback from FDA on its End of Phase 2 meeting package in June 2023 -- Completed
AccesswireNov 9, 2023 16:05 ET
Dermata Therapeutics Completes Start-Up Activities to Support DMT310 Phase 3 STAR-1 Acne Trial
- Dermata is prepared to initiate DMT310 Phase 3 STAR-1 clinical trial by the end of 2023 -- Investigational sites have been selected -- Clinical trial materials are ready to be shipped to investigati
AccesswireOct 26, 2023 09:00 ET
Dermata to Present at the H.C. Wainwright 25th Annual Global Investment Conference
AccesswireAug 31, 2023 09:10 ET
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
- Raised an aggregate of $6.8 million in gross proceeds from two financings completed in 1H 2023 -- Received positive feedback on its End of Phase 2 meeting package from FDA in June 2023 -- Phase 3 ST
AccesswireAug 10, 2023 16:15 ET
Dermata Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
SAN DIEGO, CA / ACCESSWIRE / June 13, 2023 / Dermata Therapeutics, Inc. (NASDAQ:DRMA, DRMAW) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical a
AccesswireJun 13, 2023 16:15 ET
Journal of the American Academy of Dermatology Publishes Positive DMT310 Phase 2b Acne Results
- DMT310 once-weekly topical treatment demonstrated statistically significant improvements at all time points in the three primary endpoints, inflammatory lesion count, noninflammatory lesion count, a
AccesswireJun 8, 2023 09:00 ET
Dermata Therapeutics Announces Closing of $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules
SAN DIEGO, CA / ACCESSWIRE / May 26, 2023 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (Nasdaq:DRMA; DRMAW), a clinical-stage biotechnology company focusing on the treatment of medical a
AccesswireMay 26, 2023 16:00 ET
Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules
Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq RulesSAN DIEGO, CA / ACCESSWIRE / May 24, 2023 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (Nasdaq
AccesswireMay 24, 2023 08:00 ET
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
- Dermata raised $5 million gross proceeds from a public offering in March 2023 -- Dermata submitted an End of Phase 2 meeting package to FDA in April 2023 -- FDA agreed that Dermata's chemistry, manu
AccesswireMay 11, 2023 16:05 ET
Dermata Announces Receipt of Type C Meeting Response From the FDA and Submission of DMT310 End of Phase 2 Meeting Package
- FDA agrees that Dermata's CMC procedures and controls support the initiation of Phase 3 studies-- Dermata also submitted an end of phase 2 meeting package to the FDA -SAN DIEGO, CA / ACCESSWIRE / Ap
AccesswireApr 20, 2023 06:00 ET
Dermata Therapeutics Announces Closing of $5.0 Million Public Offering
SAN DIEGO, CA / ACCESSWIRE / March 20, 2023 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA)(NASDAQ:DRMAW), a clinical-stage biotechnology company focusing on the treatment of
AccesswireMar 20, 2023 16:31 ET
Dermata Therapeutics Announces Pricing of $5.0 Million Public Offering
AccesswireMar 16, 2023 13:22 ET
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2022 Financial Results
- End of Phase 2 meeting with FDA for DMT310 for moderate-to-severe acne expected in 2Q 2023 -- Initiation of DMT310 Phase 3 clinical trial program in moderate-to-severe acne patients expected in 2H 2
AccesswireFeb 21, 2023 16:08 ET
No Data
No Data